.jpg)
23.Comparison Between the Effect of Calcium Carbonate versus Calcium Acetate on Hyperphosphatemia in Patients with End Stage Kidney Disease
Samee Ullah Khan, Muhammad Naveed Jabbar, Aneeqa Nawaz, Adeela Saif and Ali Waqas
ABSTRACT
Objective: To compare phosphate binding power and hypercalcemic effect of calcium acetate and calcium carbonate in patients of end stage renal disease on maintenance hemodialysis.
Study Design: Randomized control trial study
Place and Duration of Study: This study was conducted at the Nephrology Department, Sahiwal Teaching Hospital, Sahiwal from March 2022 to February 2023.
Materials and Methods: Seventy patients on hemodialysis were enrolled and divided into two groups by simple random numbering technique. Patients were given calcium acetate and calcium carbonate for period of two months after washout period of two weeks. Serum phosphate, calcium and albumin were noted. SPSS version 24 was used for data analysis.
Results: The average Ca (CaAc) and Ca (CaCO3) of the patients was 2.31±0.17 and 2.82±0.11, respectively. The difference was statistically significant, (p<0.001). The average Po4 (CaAc) and Po4 (CaCO3) of the patients was 1.28±0.19 and 1.71±0.10, respectively. The difference was statistically significant, (p<0.001). Whereas, the average albumin (phase-II) and albumin (phase-IV) of the patients was 38.59±3.42 and 34.72±4.49, respectively. The difference was statistically significant, (p<0.001).
Conclusion: Calcium acetate and calcium carbonate have a similar effect on serum phosphate levels and tolerance is also same. Calcium acetate results in a lesser frequency of hypercalcemia compared to calcium carbonate.
Key Words: Calcium carbonate, Calcium Acetate, Phosphate binding, Hemodialysis, end stage renal disease.